Safety Results and Analysis of Eribulin Efficacy according to Previous Microtubules-Inhibitors Sensitivity in the French Prospective Expanded Access Program for Heavily Pre-treated Metastatic Breast Cancer.
Fiche publication
Date publication
décembre 2017
Journal
Cancer research and treatment : official journal of Korean Cancer Association
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PIVOT Xavier
Tous les auteurs :
Sabatier R, Diéras V, Pivot X, Brain E, Roché H, Extra JM, Monneur A, Provansal M, Tarpin C, Bertucci F, Viens P, Zemmour C, Gonçalves A
Lien Pubmed
Résumé
Eribulin is approved for advanced breast cancers refractory to anthracyclines and taxanes. Efficacy according to sensitivity to previous therapies has been poorly explored.
Mots clés
Eribulin, Metastatic breast cancer, Microtubule inhibition, Safety, Survival
Référence
Cancer Res Treat. 2017 Dec 28;: